Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Dosing and Feeding Intervals on Hetrombopag Olamine PK
NCT03603132Phase 1Completed
- Sponsor
- Hengrui
- Start
- Jul 2018
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of hetrombopag in immune thrombocytopenia (ITP) (3 arms), sponsored by Hengrui. Primary endpoint: Adverse events at Day 26. Started Jul 2018; status: completed.
02
Drugs
hetrombopag
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT03603132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03603132.